Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Int J Biol Macromol ; 233: 123223, 2023 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-36639070

RESUMO

Tailoring magnetic nanocarriers with tunable properties is of great significance for the development of multifunctional candidate materials in numerous fields. Herein, we report a one-pot biomimetic silicification-based method for the synthesis of silica-coated magnetic nanoparticles. The synthesis process was mild, low cost, and highly efficient, which took only about 21 min compared with 4.5-120 h in other literature. Then, the carriers had been characterized by VSM, SEM, TEM, XRD, FT-IR, and EDS to confirm their function. To evaluate the usefulness of the carriers, they were adopted to couple the purification and immobilization of ß-1,3-xylanase from the cell lysate in a single step with high immobilization yield (92.8 %) and high activity recovery (82.4 %). The immobilized enzyme also retained 58.4 % of the initial activity after 10 cycles and displayed good storage properties, and improved thermal stability, which would be promising in algae biomass bioconversion as well as other diverse applications.


Assuntos
Nanopartículas de Magnetita , Nanopartículas , Dióxido de Silício , Espectroscopia de Infravermelho com Transformada de Fourier , Enzimas Imobilizadas/metabolismo , Fenômenos Magnéticos , Estabilidade Enzimática , Concentração de Íons de Hidrogênio , Temperatura
2.
Virology ; 570: 57-66, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-35367742

RESUMO

Virus-like particles (VLPs) from Parvovirus B19 (B19V) can be obtained by the self-assembly of the structural proteins VP1 and VP2. It is possible to produce B19V VLPs either from VP2 or a mixture of VP1 and VP2, through its heterologous expression in eukaryotic cells. The difference between VP1 and VP2 protein is a tract of 227 residues located at the N-terminal region of VP1, known as the VP1 unique region (VP1u). This region is critical for B19V infection, including tropism, cell internalization, and lysosomal scape through its phospholipase 2A activity. Herein, we report the in vitro self-assembly of VP1 to form VLPs. These species have phospholipase activity, suggesting that the phospholipase domain is correctly folded. Furthermore, VP1 and VP2 were co-assembled to produce hybrid VLPs which were able to bind and internalize in the non-permissive HepG2 cells, another evidence of the functionality of the in vitro refolded VP1u.


Assuntos
Parvovirus B19 Humano , Proteínas do Capsídeo/metabolismo , Parvovirus B19 Humano/genética , Fosfolipases
3.
Virus Res ; 255: 1-9, 2018 08 15.
Artigo em Inglês | MEDLINE | ID: mdl-29964063

RESUMO

The natural properties of virus-like particles (VLPs), like their nanometric size, polyvalence, monodispersity and biocompatibility, had called the attention of scientists from different fields. VLPs constitute an excellent platform for the development nanomaterials with a broad spectrum of applications, ranging from physics of soft matter to the development of vaccines and biological nanocarriers. To expand the repertoire of functions of VLPs, they can be decorated with different molecules. In this research, the α-glucosidase Ima1p of Saccharomyces cerevisiae was attached to the surface of in vitro assembled VLPs of parvovirus B19, by using the SpyTag/SpyCatcher system. The resulting particles were structurally characterized displaying a noticeable increase in size compared to the non-decorated VLPs. The study of the biochemical properties of the coupled enzyme indicate that it increased its Vmax by three-fold toward p-nitrophenyl-α-D-glucopyranoside (p-NPG) as substrate. In addition, the linked enzyme displayed a notorious 10 °C shift in its optimal temperature, from 35 °C for the non-attached enzyme, to 45 °C for the enzyme attached to VLPs. The decorated VLPs were also able to act on glycogen; therefore, these particles may be further developed as part of the therapy for treatment of lysosomal storage diseases derived from defects in the human acid α-glucosidase.


Assuntos
Proteínas do Capsídeo/química , Sistemas de Liberação de Medicamentos/métodos , Nanopartículas/química , Nanopartículas/metabolismo , Parvovirus B19 Humano/química , alfa-Glucosidases/química , Proteínas do Capsídeo/genética , Proteínas do Capsídeo/metabolismo , Glucosídeos/metabolismo , Glicogênio/metabolismo , Concentração de Íons de Hidrogênio , Cinética , Nanopartículas/ultraestrutura , Tamanho da Partícula , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/metabolismo , Estrutura Terciária de Proteína , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/metabolismo , Temperatura , Montagem de Vírus , alfa-Glucosidases/genética , alfa-Glucosidases/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA